MENU

Can DexCom (DXCM) Stock Reach $100?

a maker of medical devices and glucose monitoring systems

A.I.Advisor
published price charts
A.I.Advisor
Nov 09, 2026

Can DexCom (DXCM) Stock Reach $100?

Key Takeaways

  • The central target of $100 is the arithmetic mean of 17 verified, current analyst price targets (roughly $99), rounded to a clean level.
  • With the latest close near $79.41, reaching $100 requires about a 26% gain — a substantial move from current levels.
  • Collected targets range from $85 (J.P. Morgan, Neutral) to $120 (Barclays, Overweight); independent aggregator averages run roughly $96–$98.
  • Supporting factors include a durable continuous glucose monitoring (CGM) franchise, a Strong Buy/Overweight ratings mix, and a cluster of post-earnings target increases.
  • Key risks include a sharp post-earnings share pullback, intensifying competition in diabetes technology, and a relatively rich valuation.
  • For more detail on the company's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages.
  • Explore Trending AI Robots to see how AI-driven trading strategies are positioning across the market.

Analyst Price Targets and Consensus View

DexCom, Inc. (DXCM) is a Nasdaq-listed medical device company and a leader in continuous glucose monitoring systems. Its stock carries an overwhelmingly positive sell-side posture: most coverage sits at Strong Buy or Overweight, with only a handful of Neutral ratings and effectively no Sell ratings in the most recent tally.

Reviewing 17 individual, attributable targets produces a wide but constructive range. The lowest current target is J.P. Morgan's $85 (Neutral), while Barclays stands at the top end with $120 (Overweight), citing a solid third-quarter report. In between sit Evercore ISI ($110), UBS ($107), RBC Capital ($105), Baird ($105), Mizuho ($100), Raymond James ($97), Canaccord ($97), BTIG ($96), Argus Research ($96), Stifel ($95), Piper Sandler ($95), Leerink Partners ($94), StoneX ($93), and Deutsche Bank ($92). The mean of these targets is approximately $99, which rounds to the $100 central target used here.

Independent aggregators report comparable figures: S&P Global's poll of 29 analysts shows a consensus near $98, while other services cluster around $96–$97. The dispersion between a cautious $85 and an aggressive $120 reflects genuine disagreement about competitive pressure, reimbursement, and how much growth investors should pay for.

Current Market Position and Path Toward the Target

DXCM last closed near $79.41, after falling about 6% in a single session and pulling back from a 52-week high around $92.59. The stock has nonetheless advanced strongly over the trailing year, with a 52-week range of roughly $54.11 to $92.59 and a market capitalization near $30 billion.

To reach $100, the shares would need to rise roughly 26%, which qualifies as a substantial move. The path would most likely depend on sustained double-digit revenue growth, stable or improving gross margins, and a rebound in investor confidence following the recent earnings-driven slide. Because the stock already trades at roughly 31 times trailing earnings (P/E, price-to-earnings ratio), further appreciation would need to be supported by earnings growth and upward estimate revisions rather than multiple expansion alone.

What Could Support a Move Toward the Target

The core bull case rests on DexCom's entrenched position in CGM, a market driven by rising diabetes prevalence and broader adoption of wearable glucose monitoring. Analysts model low-double-digit revenue growth over the next year, with several firms raising targets immediately after the third-quarter report — a signal that underlying demand and execution are holding up. A Strong Buy consensus and an almost complete absence of sell ratings provide a supportive backdrop. Reimbursement stability in key channels and ongoing product innovation also underpin longer-term confidence.

What Could Prevent the Target From Being Reached

The sharp post-earnings decline is the most immediate caution flag, suggesting the market found something in the quarter or guidance to be cautious about. Competition in diabetes technology remains intense, and a relatively elevated valuation leaves little room for execution missteps or guidance cuts. If revenue growth decelerates, margins compress, or analysts begin trimming targets — as some have in prior quarters — the shares could consolidate below $100 for an extended period. A broad rotation away from growth and medtech names would add further pressure.

Technical Levels and Market Structure

The most durable reference points are the 52-week high near $92.59, which now acts as the principal resistance zone on any recovery, and the 52-week low near $54.11. The recent slide below the mid-$80s area leaves the stock testing support near its post-earnings lows around $79, with the psychological $80 level and, lower down, the mid-$70s as additional zones to watch. Regaining and holding the low-to-mid $80s would be a meaningful first step toward rebuilding the longer-term uptrend.

Time Horizon and What Investors Should Monitor

Most analyst price targets reflect a research horizon of roughly 12 months, though individual assumptions vary by firm and model. Investors focused on the path toward $100 should watch the next quarterly earnings report and forward guidance, gross margin and pricing trends, analyst estimate and target revisions, competitive product launches, and any updates on reimbursement and regulatory policy. Macro factors such as interest-rate expectations and medtech sector sentiment also matter for a growth-multiple stock.

AI Daily Buy/Sell Signals

AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like DXCM, these signals can help traders spot shifting trends, identify entry and exit points, and manage positions more efficiently than manual chart review. Whether you are tracking a single holding or scanning the broader market, the tool offers a systematic way to stay ahead of momentum changes.

Final Assessment

The $100 central target reflects the average of 17 verified analyst price targets and sits well above the current price near $79.41, implying a substantial — but not extreme — 26% move. The bull case is grounded in a resilient CGM franchise, a strongly positive ratings mix, and a wave of post-earnings target increases. The bear case centers on the stock's recent slide, competitive intensity, and a valuation that demands continued flawless execution. With targets spanning $85 to $120, Wall Street is clearly split on how far the rally can extend. Whether DXCM reaches $100 will likely hinge on the next few earnings prints and whether revenue growth and margin trends justify the premium investors are asked to pay.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

DXCM and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DXCM has been loosely correlated with ISRG. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if DXCM jumps, then ISRG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DXCM
1D Price
Change %
DXCM100%
-1.08%
ISRG - DXCM
46%
Loosely correlated
-2.01%
ALGN - DXCM
44%
Loosely correlated
-2.82%
LIVN - DXCM
42%
Loosely correlated
-1.46%
PODD - DXCM
41%
Loosely correlated
-2.96%
NVST - DXCM
40%
Loosely correlated
-1.55%
More

Groups containing DXCM

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DXCM
1D Price
Change %
DXCM100%
-1.08%
Health Services
category (238 stocks)
2%
Poorly correlated
-2.69%
Medical/Nursing Services
category (138 stocks)
1%
Poorly correlated
-3.38%
Can DexCom (DXCM) Stock Reach $100?